

18 August 2020

## Resignation of Andy Jane from the Board of Directors

**Minnesota, United States and Melbourne, Australia – 18 August 2020** – Osprey Medical, Inc. (ASX:OSP) (**Osprey or the Company**) today announces the resignation of Andy Jane from its Board of Directors. Mr Jane is a Managing Director with Talu Ventures, formerly CM Capital Investments, which is currently a security holder in the Company. Mr Jane has served as a director of the Company since November 2012 and has provided valuable insight and assistance to the Company during this time.

Osprey’s Chairman, John Erb, said “We would like to thank Andy for his service to Osprey and the assistance that he has provided to the Board in recent years. Talu Ventures has been a strong supporter of the Company since its inception and the Company has benefited from the sound guidance and direction from Mr Jane.”

The Company intends to appoint an additional independent director to its Board to replace Mr Jane in the near term. The Company is currently at an important juncture of growth as it enters into its global commercial growth phase following the exclusive agreement with GE Healthcare to distribute its products across Europe, Russia, Middle East, Africa, Central Asia and Turkey.

**This release dated 18 August 2020 has been authorised for lodgement to ASX by Mike McCormick, CEO of Osprey Medical.**

– ENDS –

### Contact details:

#### Investors relations

Leijie Li  
Vesparum Capital  
T: (61) 3 8582 4800  
[ospreymed@vesparum.com](mailto:ospreymed@vesparum.com)

#### Company

Brendan Case  
Company Secretary  
M: (61) 410 442 393  
[brendan@casegovernance.com.au](mailto:brendan@casegovernance.com.au)

### About Osprey Medical (ASX: OSP)

Osprey Medical’s vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient’s risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company’s DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s advisory board comprises world-recognised experts in heart and kidney diseases. Follow us on [LinkedIn](#) and [Twitter](#) for the latest news, or visit our website [www.ospreymed.com](http://www.ospreymed.com) for more information.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks,

uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

#### **Foreign Ownership Restriction**

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.